Psychiatr. praxi 2017; 18(3): 129-132 | DOI: 10.36290/psy.2017.024

The issue of tardive dyskinesia, focusing on the therapeutic potential of tetrabenazine

prof. MUDr. Klára Látalová, Ph.D.
Klinika psychiatrie FN Olomouc a LF UP v Olomouci

Wider use of atypical antipsychotics has reduced the prevalence and incidence of tardive dyskinesia (TD), but TD appearsto be a problem at times. Tardive dyskinesia is resistant to numerous treatment interventions. Clonazepam, amantadine,ginkgo biloba extract and tetrabenazine are more convincing results. Tardive dyskinesia persists even after discontinuationof antipsychotics and, moreover, after their discontinuation, signs of dyskinesia are often highlighted. All antipsychoticsto some extent antagonize dopamine, therefore their use will always be associated with the risk of TD even in modernpsychiatry. Interest in the possibility of targeted TD treatment was raised by new findings on genetic risk factors andpathophysiology.

Keywords: tardive dyskinesia, treatment, antipsychotics, tetrabenazine

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Látalová K. The issue of tardive dyskinesia, focusing on the therapeutic potential of tetrabenazine. Psychiatr. praxi. 2017;18(3):129-132. doi: 10.36290/psy.2017.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Faurbye A, Rash PJ, Peterson PB, Branborg G, Pekkenberg G. Neurological symptoms in pharmacotherapy of psychoses. Acta Psych Scand 2003; 40: 10-27. Go to original source... Go to PubMed...
    2. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psych 1994; 51: 483-486. Go to original source... Go to PubMed...
    3. Shonecker M. Research diagnosis for tardive dyskinesia. Arch Gen Psych 1982; 39: 486-487. Go to original source... Go to PubMed...
    4. Kraepelin E. Dementia praecox and Paraphrenia, Edinburg, Scotland: E&S Livingstone, 1919.
    5. Bleuler E. Dementia praecox of the Group of Schizophrenia, New Yourk, Ny: International Universties Press, 1950.
    6. Češková E, Švestka J, Peška I, et al. Pozdní dyskinéze při dlouhodobé léčbě neuroleptiky - souhrn literatury a vlastní zkušenosti s jejich léčbou. Čs.psychiatrie, 1990; 86(4): 269-274.
    7. Maršálek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000; 33(Supll1): 14-33. Go to original source... Go to PubMed...
    8. Merrill RM, Lyon JL. Maliaco PM. Tardive and spontaneous dyskinesia incidence in the general population, BMC Psychiatry 2013; 13: 152-160. Go to original source... Go to PubMed...
    9. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000; 6(Suppl4): S-9.
    10. Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectrum 2016; 21: 16-23. Go to original source... Go to PubMed...
    11. Teo JT, Edward MJ, Bhatia K. Tardive dyskinesia caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord 2012; 27(10): 1205-1215. Go to original source... Go to PubMed...
    12. Cloud IJ, Zutshi D, Factor SA. Tardive dyskinesia: Therapeutic options for an increasingly common disorder. Neurotherapuetica. 2014; 11: 166-176. Go to original source... Go to PubMed...
    13. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013; 14(1): 2-44. Go to original source... Go to PubMed...
    14. Bhidayuiri R. Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. 2013; 81(5): 463-469. Go to original source... Go to PubMed...
    15. Salem H, Pigott T, Zhang XY, Zeni CP, Teixeira AL. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. Expert Rev Neurother. 2017 17(9): 883-894. Go to original source... Go to PubMed...
    16. Thalter GK, Nguyen JA. Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiat 1990; 147(4): 445-451. Go to original source... Go to PubMed...
    17. PappaS, Toouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinelia: a randomized, double-blind, placebo controled studies. Clin Neuropharmacol. 2010; 33(6): 271-275. Go to original source... Go to PubMed...
    18. Zhang WF, Tan YL, Zhang XY, et al. Exctract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, plaeebo-controlled trial. J Clin Psychiatry 2011; 72(5): 615-621. Go to original source... Go to PubMed...
    19. Kazamauuri H, Chien C, Culc JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972; 27(1): 95-99. Go to original source... Go to PubMed...
    20. Erickson JD, Eiden LE, Scllafcr MK, Weihe E. Reserpine- and tetrabenazine-sensitive transport of (3)H-Histamine by the neuronal isoform of the vesicular monoamine transporter. J Mol Neurosci 1995: 6(4): 277-287. Go to original source... Go to PubMed...
    21. www.sukl.cz/download/spc/SPC123426.doc (31.7. 217)
    22. Mehanna R. Hunter C, Davidson A. Jimeecz-Shared J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord 2013; 28(2): 210-215. Go to original source... Go to PubMed...
    23. Ingrezza (valbenazine): highlights of prescribing information. April 2017. http://ingrezza.com/HCP/PI. Accessed June 16, 2017.
    24. Meyer JM. Valbenazine for tardive dyskinesia. Curr Psychiatr. 2017; 16(5): 40-46.
    25. Austedo (deutetrabenazine): highlights of prescribing information. August 2017. https://www.austedo.com/pi. Accessed September 6, 2017.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.